MARKET

INSM

INSM

Insmed Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.70
+1.51
+8.30%
After Hours: 19.70 0 0.00% 16:42 05/16 EDT
OPEN
18.41
PREV CLOSE
18.19
HIGH
20.01
LOW
18.30
VOLUME
2.27M
TURNOVER
0
52 WEEK HIGH
34.44
52 WEEK LOW
16.41
MARKET CAP
2.35B
P/E (TTM)
-5.2094
1D
5D
1M
3M
1Y
5Y
Insmed stock rises 8% after director Melvin Sharoky buys shares worth $344,000
Insmed (NASDAQ:INSM +8.4%) is trading higher after the company's director Melvin Sharoky bought 20,000 shares of the stock for an average price of $17.2 per share The total value adds up
Seekingalpha · 2h ago
Trade Alert: The Independent Director Of Insmed Incorporated (NASDAQ:INSM), Melvin Sharoky, Has Just Spent US$344k Buying 8.7% More Shares
Potential Insmed Incorporated ( NASDAQ:INSM ) shareholders may wish to note that the Independent Director, Melvin...
Simply Wall St. · 1d ago
--Berenberg Bank Adjusts Insmed's Price Target to $46 From $48, Maintains Buy Rating
MT Newswires · 05/09 07:52
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to 10 new employees. In accordance with NASDAQ Listing R...
PR Newswire · 05/06 12:00
Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of 12.09% and 0.98%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 13:05
Insmed: Q1 Earnings Insights
  Insmed (NASDAQ:INSM) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Benzinga · 05/05 12:12
Insmed Q1 EPS $(0.80) Beats $(0.88) Estimate, Sales $53.10M Miss $53.36M Estimate
Insmed (NASDAQ:INSM) reported quarterly losses of $(0.80) per share which beat the analyst consensus estimate of $(0.88) by 9.09 percent. This is a 10.11 percent increase over losses of $(0.89) per share from the same
Benzinga · 05/05 11:46
Insmed GAAP EPS of -$0.80 beats by $0.10, revenue of $53.1M misses by $0.26M
Insmed press release (NASDAQ:INSM): Q1 GAAP EPS of -$0.80 beats by $0.10. Revenue of $53.1M (+32.1% Y/Y) misses by $0.26M.
Seekingalpha · 05/05 11:39
More
No Data
Learn about the latest financial forecast of INSM. Analyze the recent business situations of Insmed Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

18.18%Strong Buy
81.82%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average INSM stock price target is 49.90 with a high estimate of 57.00 and a low estimate of 40.00.
High57.00
Average49.90
Low40.00
Current 19.70
EPS
Actual
Estimate
-0.86-0.64-0.43-0.21
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 311
Institutional Holdings: 142.70M
% Owned: 119.40%
Shares Outstanding: 119.52M
TypeInstitutionsShares
Increased
74
4.25M
New
36
1.17M
Decreased
70
5.26M
Sold Out
14
355.69K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.23%
Pharmaceuticals & Medical Research
+1.02%
Key Executives
Chairman/President/Chief Executive Officer/Director
William Lewis
Chief Financial Officer
Sara Bonstein
Chief Operating Officer
Roger Adsett
Chief Human Resource Officer
S. Nicole Schaeffer
Senior Vice President/General Counsel
Michael Smith
Other
Martina Flammer
Lead Director/Independent Director
David Brennan
Independent Director
Alfred Altomari
Independent Director
Elizabeth Anderson
Independent Director
Clarissa Desjardins
Independent Director
Steinar Engelsen
Independent Director
Leo Lee
Independent Director
David McGirr
Independent Director
Carol Schafer
Independent Director
Melvin Sharoky
No Data
No Data
About INSM
Insmed Incorporated is a global biopharmaceutical company. The Company's product, ARIKAYCE (amikacin liposome inhalation suspension) is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The Company's clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which the Company is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases. TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which offers a differentiated product profile for pulmonary arterial hypertension (PAH) and other rare pulmonary disorders.

Webull offers kinds of Insmed Incorporated stock information, including NASDAQ:INSM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INSM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading INSM stock methods without spending real money on the virtual paper trading platform.